The paradox of clozapine in Black people with treatment-resistant schizophrenia

被引：0

作者：

Whiskey, Eromona ^{[1
,2
]}

Bachmann, Christian ^{[3
]}

Dzahini, Olubanke ^{[1
,2
]}

Taylor, David ^{[1
,2
]}

Oloyede, Ebenezer ^{[1
,4
]}

机构：

[1] Maudsley Hosp & Inst Psychiat, Pharm Dept, London, England

[2] Kings Coll London, Inst Pharmaceut Sci, London, England

[3] Univ Hosp Ulm, Dept Child & Adolescent Psychiat, Ulm, Germany

[4] Univ Oxford, Dept Psychiat, Oxford, England

来源：

NATURE MENTAL HEALTH | 2025年 / 3卷 / 04期

关键词：

BENIGN ETHNIC NEUTROPENIA; UNTREATED PSYCHOSIS; MENTAL-HEALTH; RACIAL DISPARITIES; PRESCRIPTION PATTERNS; DURATION; PATHWAYS; DISCONTINUATION; CARE; SERVICES;

D O I：

10.1038/s44220-025-00411-9

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Clozapine is currently the only licensed medication for treatment-resistant schizophrenia (TRS). Ethnic inequalities in treatment with clozapine have been described extensively, particularly regarding the effect on Black ethnic groups. Here we explore the reasons for clozapine underuse in this population, identifying potential misconceptions and providing suggestions to address these barriers.

引用

页码：402 / 407

页数：6

共 85 条

[31] Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program [J].

Herman, William H. ;

MA, Yong ;

Uwaifo, Gabriel ;

Haffner, Steven ;

Kahn, Steven E. ;

Horton, Edward S. ;

Lachin, John M. ;

Montez, Maria G. ;

Brenneman, Tina ;

Barrett-Connor, Elizabeth .

DIABETES CARE, 2007, 30 (10) :2453-2457

[32] Association Between Race/Ethnicity and Disparities in Health Care Use Before First-Episode Psychosis Among Privately Insured Young Patients [J].

Heun-Johnson, Hanke ;

Menchine, Michael ;

Axeen, Sarah ;

Lung, Khristina ;

Claudius, Ilene ;

Wright, Tyler ;

Seabury, Seth A. .

JAMA PSYCHIATRY, 2021, 78 (03) :311-319

[33] The Effect of Race-Ethnicity on the Comparative Effectiveness of Clozapine Among Medicaid Beneficiaries [J].

Horvitz-Lennon, Marcela ;

Donohue, Julie M. ;

Lave, Judith R. ;

Alegria, Margarita ;

Normand, Sharon-Lise T. .

PSYCHIATRIC SERVICES, 2013, 64 (03) :230-237

[34]

IDANPAANHEIKKILA J, 1975, LANCET, V2, P611

[35] Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records [J].

Ingimarsson, Oddur ;

MacCabe, James H. ;

Haraldsson, Magnus ;

Jonsdottir, Halldora ;

Sigurdsson, Engilbert .

NORDIC JOURNAL OF PSYCHIATRY, 2016, 70 (06) :450-455

[36]

KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789

[37] Addressing Barriers to Clozapine Underutilization: A National Effort [J].

Kelly, Deanna L. ;

Freudenreich, Oliver ;

Sayer, Mackenzie A. ;

Love, Raymond C. .

PSYCHIATRIC SERVICES, 2018, 69 (02) :224-227

[38] Predictors of clozapine discontinuation in patients with schizophrenia [J].

Krivoy, Amir ;

Malka, Liron ;

Fischel, Tsvi ;

Weizman, Abraham ;

Valevski, Avi .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2011, 26 (06) :311-315

[39] Racial disparities in antipsychotic prescription patterns for patients with schizophrenia [J].

Kuno, E ;

Rothbard, AB .

AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (04) :567-572

[40] The impact of clozapine on hospital use: a systematic review and meta-analysis [J].

Land, R. ;

Siskind, D. ;

McArdle, P. ;

Kisely, S. ;

Winckel, K. ;

Hollingworth, S. A. .

ACTA PSYCHIATRICA SCANDINAVICA, 2017, 135 (04) :296-309

← 1 2 3 4 5 6 7 8 9 →